 capacity lung nifedipine systemic sclerosis Lung involvement systemic sclerosis due part functional abnormality pulmonary vasculature possible role pulmonary vasospastic process disorder non-smoking patients evidence cardiac disease pulmonary hypertension pulmonary function tests administration nifedipine minutes single oral dose nifedipine mg weeks treatment nifedipine times Treatment nifedipine pulmonary function values carbon monoxide capacity DLCO linear trend individual DLCO values baseline changes initial dose nifedipine weeks treatment DLCO value baseline improvement nifedipine findings hypothesis reversible pulmonary vasospasm systemic sclerosis nifedipine useful treatment lung disease patients studies